About this resource:

Systematic review

Source: The Cochrane Collaborative

Last Reviewed: June 2017

Workgroups: Arthritis Workgroup

This Cochrane systematic review assesses the benefits and harms of celecoxib, a selective non-steroidal anti-inflammatory drug (NSAID), in people with rheumatoid arthritis. This systematic review included 8 randomized control trials with durations of 4 to 24 weeks, published between 1998 and 2014, that involved a total of 3,988 adults (mean age = 54 years), most of whom were women (73%), and found that celecoxib may improve clinical symptoms, alleviate pain, and contribute to little or no difference in physical function compared with placebo.

Read more about this resource

Suggested Citation


Fidahic,  M., Jelicic Kadic,  A., Radic,  M. & Puljak,  L. Celecoxib for rheumatoid arthritis. Cochrane Database of Systematic Reviews, 2017 (6). DOI: 10.1002/14651858.CD012095.pub2.